EphB4 expression and biological significance in prostate cancer

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4623-4632

  Xia, Guangbin ^a   Kumar, S Ram ^a   Masood, Rizwan ^a   Zhu, Sutao ^a   Reddy, Ramchandra ^b   Krasnoperov, Valery ^b   Quinn, David I ^a   Henshall, Susan M ^c   Sutherland, Robert L ^c   Pinski, Jacek K ^a   Daneshmand, Siamak ^a   Buscarini, Maurizio ^a   Stein, John P ^a   Zhong, Chen ^a   Broek, Daniel ^a   Roy Burman, Pradip ^a   Gill, Parkash S ^a,b,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Vasgene Therapeutics Inc   (United States)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; EPHRIN RECEPTOR B4; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SMALL INTERFERING RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; EPITHELIUM CELL; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; RECEPTOR, EPHB4; RNA, MESSENGER; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 21144433227     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2667     Document Type: Article

References (52)

1. Nomura AM, Kolonel LN. Prostate cancer: a current perspective. Epidemiol Rev 1991;13:200-27.
2. Brewster SF, Gillatt DA. Advanced prostate cancer: what's new in hormonal manipulation? Br J Hosp Med 1993:49:710-1, 714-5.
3. Griffiths K, Eaton CL, Harper ME, Turkes A, Peeling WB. Hormonal treatment of advanced disease: some newer aspects. Semin Oncol 1994;21:672-87.
4. Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A. Bologna M. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol 2003;129:165-74.
5. Nickerson T. Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001;61:6276-80.
6. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62:2942-50.
7. Zhong C, Yang S, Huang J, Cohen MB, Roy-Burman P. Aberration in the expression of the retinold receptor, RXRα, in prostate cancer. Cancer Biol Ther 2003;2: 179-84.
8. Eastham JA, Grafton W, Martin CM, Williams BJ. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J Urol 2000;164:814-9.
9. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
10. Quinn DI, Henshall SM, Head DR, et al. Prognostic significance of p53 nuclear accumulation In localized prostate cancer treated with radical prostatectomy. Cancer Res 2000;60:1585-94.
11. Levitzki A. Targeting signal transduction for disease therapy. Curr Opin Cell Biol 1996;8:239-44.
12. Pasquale EB. The Eph family of receptors. Curr Opin Cell Biol 1997;9:608-19.
13. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand Ephrin-B2 in cardiovascular development. Mol Cell 1999;4:403-13.
14. Tickle C, Altabef M. Epithelial cell movements and interactions in limb, neural crest and vasculature. Curr Opin Genet Dev 1999;9:455-60.
15. Holder N, Klein R. Eph receptors and ephrins: effectors of morphogenesis. Development 1999;126: 2033-44.
16. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998;93:741-753.
17. Adams RH, Wilkinson GA, Weiss C, et al. Holes of ephrin B ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999;13:295-306.
18. Shin D, Garcia-Cardena G, Hayashi S, et al. Expression of Ephrin-B2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of micro-vessels at sites of adult neovascularization. Dev Biol 2001;230:139-50.
19. Brambilla R, Schnapp A. Casagranda F, et al. Membrane-bound LERK2 ligand can signal through three different Eph-related receptor tyrosine kinases. EMBO J 1995;14:3116-26.
20. Sakano S, Serizawa R, Inada T, et al. Characterization of a ligand for receptor protein-tyrosine kinase HTK expressed in Immature hematopoietic cells. Oncogene 1996;13:813-22.
21. Davis S, Gale NW, Aldrich TH, et al. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 1994;266:816-9.
22. Gale NW, Yancopoulos GD. Ephrins and their receptors: a repulsive topic? Cell Tissue Res 1997;290:227-41.
23. Bruckner K, Pasquale EB, Klein R. Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science 1997;275:1640-3.
24. Holland SJ, Gale NW, Mbamalu G, Yancopoulos GD, Henkemeyer M, Pawson T. Bidirectional signalling through the EPH-family receptor Nuk and its trans-membrane ligands, Nature 1996;383:722-5.
25. Fuller T, Korff T, Kilian A, Dandekar G, Augustin HG. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from Ephrin-B2 positive cells. J Cell Sci 2003;116:2461-70.
26. Hamada K, Oike Y, Ito Y, et al. Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells. Arterioscler Thromb Vase Biol 2003;23:190-7.
27. Oates AC, Lackmann M, Power MA, et al. An early developmental role for eph-ephrin interaction during vertebrate gastrulation. Mech Dev 1999;83:77-94.
28. O'Leary DD, Wilkinson DG. Eph receptors and ephrins in neural development. Curr Opin Neurobiol 1999;9:65-73.
29. Steinle JJ, Meininger CJ, Forough R, Wu G, Wu MH, Granger HJ, Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J Biol Chera 2002;277:43830-5.
30. Stephenson SA, Slomka S, Douglas EL, Hewett PJ, Hardingham JE. Receptor protein tyroslne kinase EphB4 is up-regulated in colon cancer, BMC Mol Biol 2001;2; 15-23.
31. Berclaz G, Andres AC, Albrecht D, et al. Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium. Biochem Biophys Res Commun 1996;226:869-75.
32. Andres AC, Zuercher G, Djonov V, Flueck M, Ziemiecki A. Protein tyrosine kinase expression during the estrous cycle and carcinogenesis of the mammary gland. Int J Cancer 1995;63:288-96.
33. Berclaz G, Karamitopoulou E, Mazzucchelli L, et al. Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. Ann Oncol 2003;14:220-6.
34. Takai N, Miyazaki T, Fujisawa K, Nasu K, Miyakawa I. Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer, Oncol Rep 2001;8:567-73.
35. Henshall SM, Afar DE, Hiller J, et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003;63:4196-203.
36. Quinn DI, Henshall SM, Haynes AM, et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 2001;19:3692-705.
37. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA, Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther 2002;1;1349-53.
38. Liu W, Akhand AA, Kato M, et al. 1.4-hydroxynonenal triggers an epidermal growth factor receptor-linked signal pathway for growth inhibition. J Cell Sci 1999;112: 2409-17.
39. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 2003;104:603-10.
40. Tang XX, Brodeur GM, Campling BG, Ikegaki N. Coexpression of transcripts encoding EphB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma. Clin Cancer Res 1999; 5:455-60.
41. Wu Q, Suo Z. Risberg B, Karlsson MG, Villman K, Nesland JM. Expression of Ephb2 and Ephb4 in breast carcinoma, Pathol Oncol Res 2004;10:26-33.
42. Berclaz G, Flutsch B, Altermatt HJ, et al. Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. Oncol Rep 2002;9:985-9.
43. Nupponen N, Visakorpi T. Molecular biology of progression of prostate cancer. Eur Urol 1999;35:351-4.
44. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998;58:2720-3.
45. Munarini N, Jager R, Abderhalden S, et al. Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. J Cell Sci 2002;115:25-37.
46. Liu ZJ, Shlrakawa T, Li Y, et al. Regulation of Notch1 and D114 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 2003; 23:4-25.
47. D'Amore PA, Ng Y-S. Won't you be my neighbor? Local induction of arteriogenesis. Cell 2002;110: 289-92.
48. Bruhl T, Urbich C, Aicher D, Acker-Palmer A, Zeiher AM, Dimmeler S. Homeobox A9 transcriptionally regulates the EphB4 receptor to modulate endothelial cell migration and tube formation. Circ Res 2004;94: 743-51.
49. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A 2004;101:5583-8.
50. Marston DJ, Dickinson S, Nobes CD. Rac-dependent trans-endocytosis of ephrinBs regulates Eph-ephrin contact repulsion. Nat Cell Biol 2003;5:879-88.
51. Zimmer M, Palmer A, Kohler J, Klein R. EphB-ephrinB bi-directional endocytosis terminates adhesion allowing contact mediated repulsion. Nat Cell Biol 2003; 5:869-78.
52. Martiny-Baron G, Korff T, Schaffner F, et al. Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 2004;6:248-57.